Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Clinical trial NCT04499924 · COMPLETED

Trial details

NCT number: NCT04499924
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma

Start date: 2021-03-22
Primary completion: 2024-04-17
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.